NASDAQ:LXRXLexicon Pharmaceuticals Stock Price, Forecast & News

Lexicon Pharmaceuticals' stock was trading at $2.27 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LXRX shares have decreased by 20.3% and is now trading at $1.81.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its quarterly earnings data on Thursday, July, 30th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.61) by $0.02. The biopharmaceutical company had revenue of $9.16 million for the quarter, compared to analyst estimates of $8.70 million. Lexicon Pharmaceuticals had a return on equity of 50.16% and a net margin of 12.26%.
View Lexicon Pharmaceuticals' earnings history.

5 brokerages have issued twelve-month price targets for Lexicon Pharmaceuticals' stock. Their forecasts range from $2.10 to $3.00. On average, they expect Lexicon Pharmaceuticals' stock price to reach $2.70 in the next year. This suggests a possible upside of 49.2% from the stock's current price.
View analysts' price targets for Lexicon Pharmaceuticals.

Media stories about LXRX stock have trended very positive on Saturday, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Lexicon Pharmaceuticals earned a daily sentiment score of 4.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 11,370,000 shares, an increase of 9.3% from the July 15th total of 10,400,000 shares. Based on an average daily volume of 1,380,000 shares, the days-to-cover ratio is currently 8.2 days. Approximately 11.0% of the company's shares are short sold.
View Lexicon Pharmaceuticals' Short Interest.

Some companies that are related to Lexicon Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), ACADIA Pharmaceuticals (ACAD), MannKind (MNKD), Gilead Sciences (GILD), Geron (GERN) and Iovance Biotherapeutics (IOVA).

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Lexicon Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (10.29%), Federated Hermes Inc. (1.60%), Marshall Wace LLP (0.87%), Bank of New York Mellon Corp (0.53%), Goldman Sachs Group Inc. (0.48%) and Wedbush Securities Inc. (0.36%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats and Sam L Barker.
View institutional ownership trends for Lexicon Pharmaceuticals.

LXRX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace LLP, and Bank of New York Mellon Corp.
View insider buying and selling activity for Lexicon Pharmaceuticals.

LXRX stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Goldman Sachs Group Inc., WINTON GROUP Ltd, Envestnet Asset Management Inc., Strs Ohio, Virtu Financial LLC, Principal Financial Group Inc., and Bank of America Corp DE. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, and Sam L Barker.
View insider buying and selling activity for Lexicon Pharmaceuticals.

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of LXRX stock can currently be purchased for approximately $1.81.

Lexicon Pharmaceuticals has a market capitalization of $193.86 million and generates $322.07 million in revenue each year. The biopharmaceutical company earns $130.13 million in net income (profit) each year or $1.35 on an earnings per share basis. Lexicon Pharmaceuticals employs 202 workers across the globe.

The official website for Lexicon Pharmaceuticals is www.lexpharma.com.

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.